TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas

Journal of Neuro-Oncology

Volumn 126, Issue 3, 2016, Pages 441-446

  Nencha, Umberto ^a   Rahimian, Amithys ^a,b   Giry, Marine ^a   Sechi, Andrea ^a   Mokhtari, Karima ^c   Polivka, Marc ^d   Schmitt, Yohann ^a   Di Stefano, Anna Luisa ^a,c   Alentorn, Agusti ^a,c   Labussière, Marianne ^a   Sanson, Marc ^a,c  

^a SORBONNE UNIVERSITÉ   (France)

^b OncoNeuroTek   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

EGFR; Glioblastoma; Polymorphism; rs2853669; TERT

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; ISOCITRATE DEHYDROGENASE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CDKN2A GENE; CHROMOSOME 10Q; CONTROLLED STUDY; FEMALE; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLIOBLASTOMA; HUMAN; IDH GENE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PROMOTER REGION; SURVIVAL TIME; TERT GENE; WILD TYPE; ADOLESCENT; AGED; BRAIN TUMOR; CANCER STAGING; FOLLOW UP; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TELOMERASE; YOUNG ADULT;

EID: 84956703933     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1999-3     Document Type: Article

References (18)

1. Shete S, Hosking FJ, Robertson LB et al (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41:899–904
2. Walsh KM, Codd V, Smirnov IV et al (2014) Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 46:731–735
3. Jones AM, Beggs AD, Carvajal-Carmona L et al (2012) TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut 61:248–254
4. Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021
5. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957–959
6. Labussière M, Boisselier B, Mokhtari K et al (2014) Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 83:1200–1206
7. Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126:931–937
8. Simon M, Hosen I, Gousias K et al (2015) TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 17:45–52
9. Arita H, Narita Y, Fukushima S et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267–276
10. Killela PJ, Pirozzi CJ, Healy P et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515–1525
11. Hsu CP, Hsu NY, Lee LW, Ko JL (2006) Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter–effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer 42:1466–1474
12. Rachakonda PS, Hosen I, de Verdier PJ et al (2013) TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A 110:17426–17431
13. Labussière M, Di Stefano AL, Gleize V et al (2014) TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 111:2024–2032
14. Park CK, Lee SH, Kim JY et al (2014) Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget 5:3399–3407
15. Spiegl-Kreinecker S, Lotsch D, Ghanim B et al (2015) Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol 17:1231
16. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154
17. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003
18. Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 372:2499–2508